Emerging and re‐emerging viral diseases can create devastating effects on human lives
and may also lead to economic crises. The ongoing COVID‐19 pandemic due to the novel …

Prompt antiviral treatment has the potential to reduce influenza virus transmission to close
contacts, but rigorous data on the magnitude of treatment effects on transmission are limited …

Given the current coronavirus disease 2019 (COVID-19) pandemic, coinfection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) is a …

Influenza remains one of the most significant public health threats due to its ability to cause
high morbidity and mortality worldwide. Although understanding of influenza viruses has …

Influenza A and B viruses are among the most prominent human respiratory pathogens.
About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths …

It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were
approved for the treatment and prevention of influenza. Guidelines for global surveillance …

Respiratory viruses, such as influenza viruses, cause significant morbidity and mortality
worldwide through seasonal epidemics and sporadic pandemics. Influenza viruses transmit …

Amino acid substitutions I38T and E23K in the influenza polymerase acidic (PA) protein lead
to reduced susceptibility to the influenza antiviral drug baloxavir. The in vivo effectiveness of …

Past pandemic influenza viruses with sustained human-to-human transmissibility have
emerged from animal influenza viruses. Employment of experimental models to assess the …

As use of the ferret model to study influenza A virus (IAV) pathogenicity increases, periodic
assessment of data generated in this model is warranted, to identify features associated with …